Latest Breaking News On - Ischemic cardiomyopathy - Page 14 : comparemela.com

Hemostemix Inc.: Hemostemix Announces Warrant Repricing and Extension Hemostemix or the Company ) is pleased to announce that it has, subject to TSX Venture Exchange Approval, repriced to $0.55 each, and extended the exercise period for two years, the Warrants expiring May 7, 2020 and May 28, 2020, subject to the accelerator provisions, such that the exercise period of Warrants will be reduced to thirty (30) days, if, for any ten consecutive trading days during the unexpired term of the Warrants, the weighted average closing price of the Company s listed shares achieves or exceeds the price of 120% of the applicable exercise price ($0.66). The 30-day expiry period commences on the day the Company either (i) disseminates a press release, or (ii) sends a written notice to the holders of the Warrants advising of the commencement of the exercise period.

United statesThomas smeenkWorld economic forum technology pioneer awardHemostemix incVenture exchange approvalRegulation service providerAlberta newsfile corpVenture exchangeInsider of the companyExchange approvalCommon shareCommon sharesOriginal private placementsMultilateral instrumentMinority shareholdersSpecial transactions